Posts tagged ‘NASDAQ:OSIR’
Cardium (CXM) Forms Medical Advisory Board To Support FDA Cleared Wound Care Product
Cardium Therapeutics Ltd. (NYSE MKT: CXM), an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and business with the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR),
Cardium Reports on Recent Developments
Cardium Therapeutics Ltd. (NYSE MKT: CXM), an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and business with the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR),
Cardium’s Wound Care Product Named As Top 10 Innovation In Podiatry
Last year, industry specialist GlobalData released a report estimating the global diabetic foot ulcer therapeutics market to be valued at $1.15 billion in 2010 with expectations of growth to $2.28 billion by 2017. A recent article by BBC News called today’s diabetic foot care “appalling” and leading to “an increased risk of having a foot amputated.” With
Cardium to Present at Marcum Conference
Cardium Therapeutics (NYSE MKT: CXM), a health sciences and regenerative company focused on the acquisition of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs and definable pathways to commercialization, like companies such as Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR), reported that
Cardium (CXM) Engages MissionIR to Expand Investor Awareness
Cardium Therapeutics (NYSE MKT: CXM), a health sciences and regenerative medicine company focused on the acquisition of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs and definable pathways to commercialization, targeting the regenerative medicine industry alongside companies like Geron Corporation (NASDAQ: GERN) and Osiris Therapeutics Inc.
May Proves to be Another Solid Month for Regenerative Medicine Industry
Each month brings more advancements in the field of regenerative medicine with May recording a major milestone as Osiris Therapeutics Inc. (NASDAQ: OSIR) announced market authorization from Health Canada to market its stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children. The landmark clearance marked the world’s first regulatory
Cardium (CXM) to Present at Sachs 2012 Science, Partner, and Investment Forum
Cardium Therapeutics (NYSE Amex: CXM), a health sciences and regenerative medicine company focused on the acquisition of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs and definable pathways to commercialization, targeting the regenerative medicine industry alongside companies like Geron Corporation (NASDAQ: GERN) and Osiris Therapeutics Inc.
World’s First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada
Osiris Therapeutics Inc. (NASDAQ: OSIR) announced today it has received market authorization from Health Canada to market its stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children. The historic decision marks the world’s first regulatory approval of a manufactured stem cell product and the first therapy approved for GvHD
Athersys (ATHX) Secures New GvHD Patent for MultiStem
Athersys Inc. (NASDAQ: ATHX), a biopharmaceutical company focused on developing an innovative stem cell platform, similar to companies like Mesoblast (ASX: MSB), Verastem Inc. (NASDAQ: VSTM) and Osiris (NASDAQ: OSIR), recently announced that it was granted a U.S. patent that covers the non-embryonic, multipotent stem cells for the reduction in severity or prevention of Graft-versus-Host
Athersys (Nasdaq: ATHX) Reports a Year of Progress in 2010, Eyes Potential in 2011
Athersys, Inc. (Nasdaq: ATHX), a clinical-stage biopharmaceutical company that has developed a unique stem cell platform, operating in the same industry as companies like Osiris Therapeutics, Inc. (Nasdaq: OSIR) and StemCells, Inc. (Nasdaq: STEM), reported a year of progress in 2010 and sees strong potential in 2011 in its latest 10-K filing with the SEC.